Topic 405: intratumoral biosensing for in vivo pharmacotyping
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00043
- Awardee
-
Lodestone Biomedical Inc. UEI KSGGUNHRF8D5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,050,000
Award facts
- Opportunity
-
- BAA75N91021R00068 Solicitation number
- Contract value 100% obligated
- $2,050,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Lebanon, NH 03766, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,050,000 |
About this award
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Lodestone Biomedical LLC, a small business. The contract, valued at $2,050,000, is for the development of "INTRATUMORAL BIOSENSING FOR IN VIVO PHARMACOTYPING" technology. The contract has a firm fixed price pricing structure and a completion date of September 18, 2024. This SBIR Phase II award is part of the NCI's research and development efforts focused on advancing innovative cancer detection and treatment technologies.
Quick answers
Who was awarded contract 75N91022C00043?
75N91022C00043 was awarded to Lodestone Biomedical Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2022.
How much is contract 75N91022C00043 worth?
The government has obligated $2,050,000 on 75N91022C00043.
Was contract 75N91022C00043 competed?
The extent of competition for 75N91022C00043 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award